Case series of complex therapy of hemoblastosis in the context of COVID-19

Vadim Kemaykin 1, Ruzal Vildanova 1, Jamilya Saparbay 2 * , Azat Karabekov 1, Zhandos Burkitabayev 3
More Detail
1 Department of Oncohematology and Bone Marrow Transplantation, National Research Oncology Center, Nur-Sultan, Kazakhstan
2 Department of Gastroenterology, Hepatology and Organ Transplantation, National Research Oncology Center, Republic of Kazakhstan
3 Chairman of the Board, National Research Oncology Center, Republic of Kazakhstan
* Corresponding Author
J CLIN MED KAZ, Volume 18, Issue 2, pp. 75-78. https://doi.org/10.23950/jcmk/9735
OPEN ACCESS
Download Full Text (PDF)

ABSTRACT

Introduction: The COVID-19 pandemic is a problem of a global scale, and it has an importance in modern oncology and hematology. Patients with cancer are at high risk of getting infected with COVID-19. Diagnosis of coronavirus infection in such patients entails the cancellation of chemotherapy for an indefinite period. A break between courses of treatment, as well as a complete cancellation of therapy, can increase the mortality of patients from oncohematological diseases.
Material and methods: From June to October 2020, based on the Oncohematological Department of the National Research Oncology Center LLP, 19 patients were treated, of which: men - 11, women - 8. Average age - 43 years (+ -16). Of these, patients with multiple myeloma - 32%; acute myeloid leukemia - 26%; acute promyelocytic leukemia - 11%; acute lymphoblastic leukemia - 26%; chronic lymphocytic leukemia - 5%. Treatment was carried out following the protocols for the diagnosis and treatment of hemoblastosis and concomitant COVID-19 infection.
Results: This article presents clinical cases of complex therapy of patients with hemoblastosis and concomitant COVID-19 infection who were treated in a hospital.

CITATION

Kemaykin V, Vildanova R, Saparbay J, Karabekov A, Burkitabayev Z. Case series of complex therapy of hemoblastosis in the context of COVID-19. J CLIN MED KAZ. 2021;18(2):75-8. https://doi.org/10.23950/jcmk/9735

REFERENCES

  • Worldometer, 2020. COVID-19 Coronavirus Pandemic. URL: https://www.worldometers.info/coronavirus/v. Accessed October 20, 2020.
  • Kazinform, 2020. COVID-19 Epidemiya koronavirusa. URL: https://www.coronavirus2020.kz. Accessed October 20, 2020.
  • Zhu WJ, Wang J, and He XH, et al (2020) [The differential diagnosis of pulmonary infiltrates in cancer patients during the outbreak of the 2019 novel coronavirus disease] Zhonghua Zhong Liu Za Zhi 42(0) E008 PMID; DOI: 10.3760/cma.j.cn112152-20200303-00166
  • Robert Weinkove, Zoe K McQuilten, Jonathan Adler, Meera R Agar, Emily Blyth, et al., «Managing haematology and oncology patients during the COVID‐19 pandemic: interim consensus guidance» Wiley Public Health Emergency Collection 2020 Jun; 212(10): 481–489DOI: 10.5694/mja2.50607
  • G.Curigliano1S.Banerjee2A.Cervantes34M.C.Garassino5P.Garrido6 et al. Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus. July 2020. DOI: 10.1016/j.annonc.2020.07.010
  • Rajkumar SV. Updated Diagnostic Criteria and Staging System for Multiple Myeloma. Am Soc Clin Oncol Educ Book. 2016;35: e418-23. DOI: 10.1200/EDBK_159009. PMID: 27249749. DOI: 10.1200/EDBK_159009
  • National Comprehensive Cancer Network www.nccn.org
  • Dadacaridou M, Papanicolaou X, Maltesas D, Megalakaki C, Patos P, Panteli K, Repousis P, Missouri-Mentzikof C. Dexamethasone, cyclophosphamide, etoposide, and cisplatin (DCEP) for relapsed or refractory multiple myeloma patients PMID: 17436400
  • Srikanth M, Davies FE, Wu P, et al. Survival and outcome of blastoid variant myeloma following treatment with the novel thalidomide containing regime DT-PACE. Eur J Haematol 2008;81:432-436 DOI: 10.1111/j.1600-0609.2008.01131.x
  • Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016; 127 (20): 2391–405. DOI: 10.1182/blood-2016-03-643544
  • Liang W, Guan W, Chen R, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020; 21 (3):335-337. DOI:10.1016/S1470-2045(20)30096-6
  • Clinical guidelines of Kazakhstan Health Care Ministry “Coronovirus infection treatment”- 10-th edition with changes from 15.07.2020.